EYPT EyePoint, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1314102 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-93.9%
TTM net income YoY-66.5%
TTM EPS YoY-32.3%
Revenue 3-yr CAGR-60.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-13,642.0%
Net margin-13,281.2%
FCF margin-11,599.4%
EBITDA margin-13,533.9%
Returns
ROE-221.9%
ROA-164.0%
ROIC (approx.)-368.4%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets34.7%
Debt / equity0.00x
Current ratio3.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-22.9%
Payout ratio—
Capex / revenue170.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $31.37M | $43.27M | $46.02M | $41.40M | $36.94M |
| R&D expense | $221.04M | $132.93M | $64.66M | $49.64M | $28.50M |
| SG&A expense | $51.61M | $52.36M | $40.10M | $34.82M | $25.57M |
| Operating income | -$243.43M | -$145.85M | -$75.07M | -$99.64M | -$55.28M |
| Interest expense | $33,000 | $14,000 | $1.25M | $3.19M | $5.50M |
| Pretax income | -$231.68M | -$130.78M | -$70.71M | -$102.25M | -$58.42M |
| Income tax | $279,000 | $90,000 | $83,000 | $0 | $0 |
| Net income | -$231.96M | -$130.87M | -$70.80M | -$102.25M | -$58.42M |
| EBITDA | -$241.12M | -$144.31M | -$74.60M | -$99.24M | -$54.97M |
| EPS (basic) | -3.17 | -2.32 | -1.82 | -2.74 | -2.03 |
| EPS (diluted) | -3.17 | -2.32 | -1.82 | -2.74 | -2.03 |
| Weighted avg. shares (diluted) | 73,251 | 56,298 | 38,904 | 37.32M | 28.76M |
| Balance sheet | |||||
| Cash & equivalents | $101.82M | $99.85M | $281.41M | $95.78M | $178.74M |
| Short-term investments | $204.26M | $271.21M | $49.79M | $48.93M | $32.97M |
| Inventory | $1.81M | $2.31M | $3.91M | $2.89M | $3.62M |
| Current assets | $328.65M | $383.31M | $344.80M | $172.81M | $237.75M |
| PP&E, net | $9.02M | $8.18M | $5.25M | $1.36M | $476,000 |
| Intangibles | — | — | — | $0 | $22.75M |
| Total assets | $364.00M | $418.46M | $355.18M | $180.36M | $263.37M |
| Current liabilities | $37.02M | $49.05M | $63.26M | $34.54M | $23.66M |
| Short-term debt | — | — | $0 | $10.47M | $0 |
| Long-term debt | — | — | — | $29.31M | $36.56M |
| Total debt | — | — | — | $39.78M | $36.56M |
| Total liabilities | $57.88M | $81.96M | $88.86M | $83.99M | $78.99M |
| Shareholders' equity | $306.11M | $336.50M | $266.32M | $96.37M | $184.38M |
| Net debt | — | — | — | -$56.00M | -$142.18M |
| Shares outstanding | 82.83M | 68.27M | 49.04M | 34.08M | 33.91M |
| Cash flow statement | |||||
| Operating cash flow | -$240.11M | -$126.23M | $1.88M | -$65.00M | -$50.10M |
| Capital expenditure | $3.28M | $4.05M | $3.48M | $2.15M | $156,000 |
| Free cash flow | -$243.39M | -$130.28M | -$1.61M | -$67.16M | -$50.25M |
| Investing cash flow | $68.58M | -$219.35M | -$3.31M | -$17.27M | -$33.12M |
| Financing cash flow | $173.65M | $164.02M | $187.07M | -$690,000 | $216.90M |
| Depreciation & amortization | $2.31M | $1.54M | $464,000 | $396,000 | $311,000 |
| Stock-based compensation | $27.87M | $36.74M | $12.06M | $14.18M | $7.45M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.